OBJECTIVE:Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) in the early years after disease onset. The aim of this study was to assess the natural history of the decline in FVC% predicted in patients receivingplacebo in the Scleroderma Lung Study and to evaluate possible factors for cohort enrichment in future therapeutic trials. METHODS: Patients randomized to receive placebo (n=79) were divided into 3 groups based on the duration of SSc (0-2 years, 2-4 years, and >4 years). Descriptive statistics and a mixed-effects model were used to analyze the rate of decline in the FVC% predicted over a 1-year period. Additional analyses stratified according to the severity of fibrosis on high-resolution computed tomography (HRCT) were performed, and interactions between disease severity and disease duration were explored. RESULTS: The mean±SD decline in the unadjusted FVC% predicted during the 1-year period was 4.2±12.8%. At baseline, 28.5%, 43.0%, and 28.5% of patients were in the groups with disease durations of 0-2 years, 2-4 years, and >4 years, respectively. The rate of decline in the FVC% predicted was not significantly different across the 3 disease groups (P=0.85). When stratified by baseline fibrosis on HRCT, the rate of decline in the FVC% predicted was statistically significantly greater in the group with severe fibrosis (mean annualized decline in the FVC% predicted 7.2% versus 2.7% in the groups with no or moderate fibrosis; P=0.008). The decline observed in the group with severe fibrosis was most pronounced in those with a relatively short disease duration (0-2 years; annualized decline 7.0%). CONCLUSION: Among patients with SSc-ILD in the Scleroderma Lung Study, the rates of progression of lung disease were similar irrespective of disease duration. The baseline HRCT fibrosis score is a predictor of a future decline in the FVC% predicted in the absence of effective treatment.
RCT Entities:
OBJECTIVE:Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) in the early years after disease onset. The aim of this study was to assess the natural history of the decline in FVC% predicted in patients receiving placebo in the Scleroderma Lung Study and to evaluate possible factors for cohort enrichment in future therapeutic trials. METHODS:Patients randomized to receive placebo (n=79) were divided into 3 groups based on the duration of SSc (0-2 years, 2-4 years, and >4 years). Descriptive statistics and a mixed-effects model were used to analyze the rate of decline in the FVC% predicted over a 1-year period. Additional analyses stratified according to the severity of fibrosis on high-resolution computed tomography (HRCT) were performed, and interactions between disease severity and disease duration were explored. RESULTS: The mean±SD decline in the unadjusted FVC% predicted during the 1-year period was 4.2±12.8%. At baseline, 28.5%, 43.0%, and 28.5% of patients were in the groups with disease durations of 0-2 years, 2-4 years, and >4 years, respectively. The rate of decline in the FVC% predicted was not significantly different across the 3 disease groups (P=0.85). When stratified by baseline fibrosis on HRCT, the rate of decline in the FVC% predicted was statistically significantly greater in the group with severe fibrosis (mean annualized decline in the FVC% predicted 7.2% versus 2.7% in the groups with no or moderate fibrosis; P=0.008). The decline observed in the group with severe fibrosis was most pronounced in those with a relatively short disease duration (0-2 years; annualized decline 7.0%). CONCLUSION: Among patients with SSc-ILD in the Scleroderma Lung Study, the rates of progression of lung disease were similar irrespective of disease duration. The baseline HRCT fibrosis score is a predictor of a future decline in the FVC% predicted in the absence of effective treatment.
Authors: J Wanger; J L Clausen; A Coates; O F Pedersen; V Brusasco; F Burgos; R Casaburi; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D Johnson; N Macintyre; R McKay; M R Miller; D Navajas; R Pellegrino; G Viegi Journal: Eur Respir J Date: 2005-09 Impact factor: 16.671
Authors: Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky Journal: N Engl J Med Date: 2006-06-22 Impact factor: 91.245
Authors: Sotiris C Plastiras; Stylianos P Karadimitrakis; Panayiotis D Ziakas; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos; George E Tzelepis Journal: Arthritis Rheum Date: 2006-08-15
Authors: Dinesh Khanna; Philip J Clements; Daniel E Furst; Yun Chon; Robert Elashoff; Michael D Roth; Mildred G Sterz; Joannie Chung; John D FitzGerald; James R Seibold; John Varga; Arthur Theodore; Fredrick M Wigley; Richard M Silver; Virginia D Steen; Maureen D Mayes; M Kari Connolly; Barri J Fessler; Naomi F Rothfield; Kamal Mubarak; Jerry Molitor; Donald P Tashkin Journal: Arthritis Rheum Date: 2005-02
Authors: Nicole S L Goh; Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Susan J Copley; Toby M Maher; Tamera J Corte; Clare R Sander; Jonathan Ratoff; Anand Devaraj; Gracijela Bozovic; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells Journal: Am J Respir Crit Care Med Date: 2008-03-27 Impact factor: 21.405
Authors: Dinesh Khanna; Xiaohong Yan; Donald P Tashkin; Daniel E Furst; Robert Elashoff; Michael D Roth; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Philip J Clements Journal: Arthritis Rheum Date: 2007-05
Authors: Charlie Strange; Marcy B Bolster; Michael D Roth; Richard M Silver; Arthur Theodore; Jonathan Goldin; Philip Clements; Joanie Chung; Robert M Elashoff; Robert Suh; Edwin A Smith; Daniel E Furst; Donald P Tashkin Journal: Am J Respir Crit Care Med Date: 2007-09-27 Impact factor: 21.405
Authors: Jonathan G Goldin; David A Lynch; Diane C Strollo; Robert D Suh; Dean E Schraufnagel; Philip J Clements; Robert M Elashoff; Daniel E Furst; Sarinnapha Vasunilashorn; Michael F McNitt-Gray; Mathew S Brown; Michael D Roth; Donald P Tashkin Journal: Chest Date: 2008-07-18 Impact factor: 9.410
Authors: Elizabeth R Volkmann; Donald P Tashkin; Masataka Kuwana; Ning Li; Michael D Roth; Julio Charles; Faye N Hant; Galina S Bogatkevich; Tanjina Akter; Grace Kim; Jonathan Goldin; Dinesh Khanna; Philip J Clements; Daniel E Furst; Robert M Elashoff; Richard M Silver; Shervin Assassi Journal: Arthritis Rheumatol Date: 2019-11-01 Impact factor: 10.995
Authors: Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin Journal: Ann Am Thorac Soc Date: 2018-11
Authors: Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee Journal: Chest Date: 2017-06-16 Impact factor: 9.410
Authors: Mona Elhaj; Julio Charles; Claudia Pedroza; Xiaochun Liu; Xiaodong Zhou; Rosa M Estrada-Y-Martin; Emilio B Gonzalez; Dorothy E Lewis; Hilda T Draeger; Sarah Kim; Frank C Arnett; Maureen D Mayes; Shervin Assassi Journal: J Rheumatol Date: 2013-04-15 Impact factor: 4.666